Vermont

The exclusion is on the drug list's own first page. Vermont's preferred drug list states in its opening notes: "Drugs used for weight loss, drugs used to promote fertility, and drugs used for cosmetic purposes or hair growth are excluded from coverage under the Vermont Medicaid Pharmacy program." The document is headed "Effective Version — Updated: 8/1/2026" and describes itself as the "Vermont Preferred Drug List and Drugs Requiring Prior Authorization (includes clinical criteria)." It also warns that it "is not an all-inclusive list of available covered drugs and includes only managed categories."

Department of Vermont Health Access, Vermont Preferred Drug List and Drugs Requiring Prior Authorization, effective August 2026 · source

Wegovy sits in a class named for the heart, and its criteria open with two things you must not be. Under "Cardiometabolic Health Agents," "Wegovy (semaglutide) subcutaneous injection" is preferred with a "QTY Limit: 4 pens/28 days" and the note "(Preferred after clinical criteria are met)"; "Wegovy (semaglutide) tablets" and "Rezdiffra (resmetirom)" are non-preferred. The criteria begin "Medication is not being used for weight loss only" and "Patient does not have diagnosis of diabetes," then require counseling on chronic weight management. The heart route asks that the "Indication for use is Major Adverse Cardiac Event (MACE) Reduction," that the "Patient has BMI > 27 kg/m2," and a history of at least one of "Stroke," "Myocardial Infarction" or "Symptomatic peripheral arterial disease." Wegovy tablets additionally need "a documented treatment failure with the preferred injectable semaglutide product." Initial approval runs six months.

Department of Vermont Health Access, Vermont Preferred Drug List and Drugs Requiring Prior Authorization, effective August 2026 · source

There is a liver route too, and Vermont puts Wegovy ahead of the drug approved for the condition. Where the "Indication for use is Metabolic Dysfunction-Associated Steatohepatitis (MASH): (injectable formulation only)," the patient must have "moderate to advanced liver fibrosis (consistent with stages F2 or F3 fibrosis) documented by either a combination of two non-invasive tests (serologic and image-based) or biopsy (NAFLD ≥ 4)," must not have "evidence of decompensated cirrhosis," and the drug must be "prescribed or in consultation with gastroenterologist, hepatologist, or endocrinologist." Rezdiffra, the drug FDA-approved for MASH, is non-preferred and its own criteria require that "Patients must have a documented side effect, allergy, contraindication, or treatment failure to Wegovy."

Department of Vermont Health Access, Vermont Preferred Drug List and Drugs Requiring Prior Authorization, effective August 2026 · source

Zepbound has a therapeutic class to itself, and it is a sleep class. Under "Obstructive Sleep Apnea," "Zepbound (tirzepatide)" is the only preferred agent, "preferred after clinical criteria are met." The criteria require a "diagnosis of obstructive sleep apnea (OSA) demonstrated by a sleep study with an AHI (events per hour) > 15" plus a "BMI > 30 kg/m2," that the patient "Has been prescribed CPAP therapy," has had chronic weight management counseling, "Does not have T2DM," "Does not have NYHA Class IV Heart Failure," and "Has not had a serious cardiac event in the previous 3 months (acute MI, stroke, unstable angina, or hospitalization due to heart failure)." Initial approval is six months, and renewal needs "a documented weight loss of > 5% of baseline body weight OR continued to maintain initial 5% weight loss."

Department of Vermont Health Access, Vermont Preferred Drug List and Drugs Requiring Prior Authorization, effective August 2026 · source

The diabetes class is a different class with a different test, and neither newer drug is in it. Under "Peptide Hormones- GLP-1 Receptor Agonists," the preferred agents are exenatide, "Mounjaro (tirzepatide)," "Ozempic (semaglutide) auto-injector pen," "Rybelsus (semaglutide) tablets," "Trulicity (dulaglutide)" and "Victoza (liraglutide)," each carrying a quantity limit. The gate is one sentence: "Clinical criteria for all drugs: patient has a diagnosis of Type 2 Diabetes Mellitus. Treatment failure for GLP-1 products is defined as <1% reduction in HbA1c after 12 weeks at the maximally tolerated dose." Wegovy and Zepbound do not appear in this class.

Department of Vermont Health Access, Vermont Preferred Drug List and Drugs Requiring Prior Authorization, effective August 2026 · source

Vermont makes you appeal to the Department first, and the two steps run on different clocks. Its member page defines the first step — "To appeal means to ask the Department to review its decision" — and states: "You must ask for an appeal within 60 calendar days of the decision." Only then does the independent step open: "You must go through the internal appeal process before you can ask for a fair hearing," and "You must ask for a Fair Hearing within 120 days from the date of the appeal decision letter." Keeping benefits running is a separate request that has to be made at the time, at both stages: "if you want your benefits or services to continue during your appeal, you must request this at the time you make your appeal," and the same instruction is repeated for the fair hearing.

Department of Vermont Health Access, Appeals, Fair Hearings and Grievances · source

The board that hears the second step publishes its own, differently worded limit, and it is older. The Human Services Board's fair hearing rules provide that appeals involving "the Office of Vermont Health Access in cases not covered by the MCO rules shall not be considered by the Board unless the applicant or recipient has made a request for fair hearing within 90 days from the date when his or her grievance with that office or department arose," while appeals "involving coverage of services or service disagreements by the Managed Care Organization (MCO)" must be made "within 90 days of the initial notice of adverse action or within 30 days of notice of the MCO internal appeal decision or as otherwise provided by law." The rules also set out how the count runs: "the day from which the designated period begins to run is not counted," and a last day falling on a weekend or holiday is excluded. The document is marked effective 9/1/08, which is why the Department's current member page above governs what a reader should do.

Vermont Human Services Board, Fair Hearing Rules 1000, Agency of Human Services, effective September 2008 · source